BALAMINES
Balaji Amines Limited (BALAMINES) gains 6% intraday
Balaji Amines Limited (NSE: BALAMINES) stock moves up 6% intraday to ₹2023.8, despite trendline status showing a breakdown.
Balaji Amines Limited (BALAMINES) surged +6% today, driven by a technical breakout as the stock cleared the key resistance at ₹1839, now trading 9.1% above this level. This move is notable as BALAMINES operates within the specialty chemicals segment of the basic materials sector, and today’s gain appears to be more company-specific rather than a sector-wide trend.
Technical setup — trendlines & DMA
The current 6-month trendline structure shows BALAMINES trading above both the support and resistance levels, indicating a breakout phase. The 6-month support trendline ends at ₹1912.9, which is 5.48% below the current price, while the resistance trendline at ₹1839.39 has been decisively broken, with the stock now trading 9.11% above it. The 50-DMA at ₹1729.3 is also below the current price, suggesting the stock is in an extended phase, currently 9.42% above this moving average. In the 52-week range of ₹968.1 to ₹2288.0, the stock is in the upper third, indicating that a substantial portion of the potential upside may already be priced in.
Snapshot: ₹2,023.80 on 2026-06-30 (chart frozen at publication)
Fundamentals & business context
With a PE of 36.7, BALAMINES appears richly valued given its profit margin of 11.7% and a declining revenue CAGR of -15.6%. This valuation suggests that the market may be pricing in a potential turnaround or future growth, despite current earnings metrics. The low institutional holding of 2.3% indicates that institutional investors are cautious about this stock, possibly due to its declining growth trends. There was no NSE catalyst today, reinforcing that the move is technical in nature.
Algorithmic scorecard
The overall algorithmic scorecard reflects a stock that is technically strong but fundamentally weak. The strongest signals include the bullish trend indicated by the 50-day average being above the 200-day average, and the bullish sentiment over the last 30 days, where volume on up days was 3.66 times higher than on down days. These signals suggest systematic accumulation and positive market sentiment. However, the weakest signals are the declining revenue and profit CAGRs, and the negligible dividend yield of 0.55%, which pose risks of continued underperformance and lack of income for investors.
Company outlook
Management outlined an optimistic forward guidance, expecting 25% to 30% volume growth in FY27 and maintaining EBITDA between 22% to 23% on total sales. They aim for a revenue target of INR3,000 crores by FY28 and plan a capex of INR275 crores to INR290 crores for the current year. Key growth drivers include the commissioning of the Dimethyl Ether (DME) plant in Q1 FY27, expected to reach 30% to 40% utilization in FY27 and 50% to 60% by the end of the year. Additionally, the N-Methyl Morpholine (NMM) project with a 5,000 TPA capacity and an improved process-based Acetonitrile (ACN) plant are slated for commissioning during FY27. The company also plans a major expansion of Balaji Specialty Chemicals Limited with an investment of INR750 crores in a phased manner.
Get all details on BALAMINES — P&L, peers, shareholding and more on TradeAlone.
BALAMINES
Balaji Amines Limited (BALAMINES) gains 6% intraday
Balaji Amines Limited (BALAMINES) stock rises 6% intraday to ₹2172.1, showing a bounce from support despite a consolidating down trendline..
Balaji Amines Limited (BALAMINES) climbed +6% to ₹2172.1 on the NSE today, reflecting a technical bounce from support rather than a breakout. The stock has transitioned from a bounce from support to consolidating down, indicating a weak structure. This move is specific to BALAMINES and does not align with broader sector momentum in specialty chemicals.
Technical setup — trendlines & DMA
The current 6-month trendline structure shows BALAMINES trading above the 6-month support trendline at ₹1959.04, which is 9.81% below today’s price, but well below the 6-month resistance trendline at ₹2525.35. The stock is currently in a breakdown phase, with the 50-DMA at ₹2154.9 above the 200-DMA at ₹1447.2, suggesting a positive but recovering trend. BALAMINES is trading in the upper third of its 52-week range, indicating that a significant portion of its move is already priced in.
Snapshot: ₹2,172.10 on 2026-08-11 (chart frozen at publication)
Fundamentals & business context
With a PE of 32.5 and profit margins at 13.4%, BALAMINES’ valuation appears stretched given its revenue CAGR of -15.6% over the past five years. The market may be pricing in a potential turnaround, but the current earnings do not justify the high PE ratio. Institutional ownership stands at a low 2.3%, indicating that smart money is cautious about this name. There was no NSE catalyst today driving the move.
Algorithmic scorecard
The overall algorithmic scorecard reflects a technically strong but fundamentally weak stock. The strongest signals include bullish sentiment with a 1.85x higher average volume on up days compared to down days, and a positive year-over-year gain of 32.2%. However, the weakest signals are the declining revenue and profit CAGRs, which indicate structural challenges in the business. Additionally, the negligible dividend yield of 0.54% offers little income to investors, despite the company’s excellent financial health with a debt-to-equity ratio of 0.00.
Company outlook
Management outlined an optimistic forward guidance for BALAMINES, targeting a 25% to 30% volume growth in FY27 and sustaining EBITDA between 22% to 23% on total sales. The company aims to achieve a revenue target of ₹3,000 crores by FY28. Key growth drivers include the commissioning of the Dimethyl Ether (DME) plant in Q1 FY27, the N-Methyl Morpholine (NMM) project with a 5,000 TPA capacity during FY27, and an improved process-based Acetonitrile (ACN) plant in Q2 FY27. Additionally, BALAMINES plans a major expansion of Balaji Specialty Chemicals Limited with an INR750 crores investment and several greenfield and brownfield projects expected to be commissioned throughout FY27.
Get all details on BALAMINES — P&L, peers, shareholding and more on TradeAlone.
BALAMINES
Balaji Amines Limited (BALAMINES) gains 5% intraday
Balaji Amines Limited (NSE: BALAMINES) stock price rises 5% intraday to ₹2116.0, bouncing from support in the Basic Materials & Specialty Chemicals sector.
Balaji Amines Limited (BALAMINES) bounced from support today, gaining +5% to ₹2116.0 on the NSE. This move comes as the stock tests its 6-month support trendline, which is currently at ₹2117.13. Balaji Amines operates in the specialty chemicals segment within the basic materials sector. Today’s bounce aligns with the stock’s recovery mode, though it remains to be seen if this move will sustain given the broader sector trends.
Technical setup — trendlines & DMA
The current trendline structure for Balaji Amines shows a 6-month support floor at ₹2117.13, just 0.05% above today’s price. Resistance is at ₹2525.35, which is 19.35% above the current price. The 50-day moving average (DMA) is at ₹2136.1, indicating that the stock is currently below this level but above the 200-DMA at ₹1431.6. This suggests the stock is in recovery mode rather than extended above both DMAs. The stock is trading in the upper third of its 52-week range, indicating that a significant portion of the move may already be priced in.
Snapshot: ₹2,116.00 on 2026-08-06 (chart frozen at publication)
Fundamentals & business context
With a PE of 33.5, profit margins at 13.4%, and a revenue CAGR of -15.6%, Balaji Amines’ valuation appears stretched relative to its current earnings. The market may be pricing in a potential turnaround, given the company’s ambitious growth targets. Institutional ownership stands at a low 2.3%, suggesting that the smart money is cautious about this name. There was no NSE catalyst today, making this move primarily technical.
Algorithmic scorecard
The overall algorithmic score of 56 reflects a technically strong but fundamentally weak profile for Balaji Amines. Two of the strongest signals are the bullish trend, indicated by the 50-DMA being above the 200-DMA, and the bullish sentiment over the last 30 days, where the stock has seen 14 up days versus 16 down days with a volume ratio of 1.89x. These signals suggest systematic accumulation and positive market sentiment. However, the company faces risks from its declining revenue and profit CAGRs, which stand at -15.6% and -19.9% respectively. Additionally, the negligible dividend yield of 0.52% offers little income for investors, making the stock more reliant on capital appreciation.
Company outlook
Management outlined an optimistic forward guidance for Balaji Amines, targeting 25% to 30% volume growth in FY27 and aiming to maintain EBITDA between 22% to 23% on total sales. The company has set a revenue target of ₹3,000 crores by FY28 and plans a capital expenditure of ₹275 crores to ₹290 crores for the current year. Growth drivers include the commissioning of the Dimethyl Ether (DME) plant in Q1 FY27, expected to reach 30% to 40% utilization by FY27 and 50% to 60% by the end of the year. Additionally, the N-Methyl Morpholine (NMM) project with a 5,000 TPA capacity is expected to be commissioned during FY27, along with an improved process-based Acetonitrile (ACN) plant in Q2 FY27. The company also plans a major expansion of Balaji Specialty Chemicals Limited with an investment of ₹750 crores in a phased manner.
Get all details on BALAMINES — P&L, peers, shareholding and more on TradeAlone.
BALAMINES
Balaji Amines Limited (BALAMINES) falls 5% intraday, breaks below support
Balaji Amines Limited (NSE: BALAMINES) drops 5% intraday to ₹2125.6, breaking below crucial support in the Specialty Chemicals sector.
Balaji Amines Limited (BALAMINES) breaks below support, falling -5% to ₹2125.6 on the NSE on 31 Jul 2026. The move comes as the stock has breached its 6-month support trendline, signaling a breakdown in the short-term trend. Balaji Amines operates in the specialty chemicals segment within the basic materials sector, and today’s decline appears to be company-specific rather than a sector-wide phenomenon.
Technical setup — trendlines & DMA
The current 6-month support trendline for Balaji Amines was at ₹2436.56, and the stock has fallen 14.63% below this level, indicating a breakdown. Resistance is at ₹2525.35, which is 18.81% above the current price. The 50-DMA is at ₹2113.0, slightly below today’s price, while the 200-DMA is at ₹1419.4, showing a significant 58.05% increase from this longer-term average. The stock is currently in the upper third of its 52-week range, suggesting that a substantial portion of its yearly highs is still priced in.
Snapshot: ₹2,125.60 on 2026-07-31 (chart frozen at publication)
Fundamentals & business context
With a PE of 35.7 and profit margins at 13.4%, Balaji Amines’ valuation appears stretched given its revenue CAGR of -15.6% over the past five years. The market may be pricing in a potential turnaround, but the current earnings and growth trajectory suggest a cautious approach. Institutional ownership stands at a mere 2.3%, indicating that the ‘smart money’ is not heavily invested in this name. There was no specific NSE catalyst today to explain the move.
Algorithmic scorecard
The overall algorithmic scorecard reflects a technically strong but fundamentally weak profile for Balaji Amines. The strongest signals include a bullish trend, with the 50-day average above the 200-day average, and bullish sentiment over the last 30 days, where up days saw 2.24 times the volume of down days. However, the weakest signals are the declining revenue and profit CAGRs, which indicate structural challenges in the business. Additionally, the negligible dividend yield of 0.48% offers little income for investors, while the high public ownership of 41.57% suggests higher volatility risk.
Company outlook
Management has provided forward-looking guidance indicating 25% to 30% volume growth in FY27 and EBITDA sustainability between 22% to 23% on total sales. The company targets INR3,000 crores in revenue by FY28 and plans a capital expenditure of INR275 crores to INR290 crores for the current year. Growth drivers include the commissioning of the Dimethyl Ether (DME) plant in Q1 FY27, the N-Methyl Morpholine (NMM) project with a 5,000 TPA capacity during FY27, and an improved process-based Acetonitrile (ACN) plant in Q2 FY27. Additionally, a major expansion of Balaji Specialty Chemicals Limited with an INR750 crores investment is planned in a phased manner.
Get all details on BALAMINES — P&L, peers, shareholding and more on TradeAlone.
-
Healthcare1 day agoLupin Limited (lupin) Receives Tentative FDA Approval for Apixaban Oral Suspension
-
Consumer Defensive1 day agoRadico Khaitan Limited Expands Global Reach: Indian Luxury Whisky Brands Land in the Home of Scotch
-
Banks - Regional1 day agoIndusind Bank Limited Launches Dedicated Banking Vertical for India’s Growing Global Capability Centres
-
Credit Services1 day agoMoneyboxx Finance Limited (moneyboxx) Raises ₹60 Crore Via Ncds
-
Capital Markets1 day agoIndian Energy Exchange Limited Expands Energy Markets Footprint
-
RATEGAIN1 day agoRategain Travel Technologies Limited (NSE: Rategain) Appoints Chetan Garg as Chief Financial Officer
-
Credit Services1 day agoIndian Railway Finance Corporation Limited Signs Rs 4,200 Crore Loan Agreement with DVC for Renewable Energy Projects
-
Healthcare1 day agoSun Pharmaceutical Industries Limited (sunpharma) Secures Global Licensing for Lerodalcibep, a PCSK9 Inhibitor